Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ACADEMIA
Nephrology Society Compiles New Drug Development Guidelines for Advanced CKD; Will Guidelines for Early-Stage CKD Follow?
The Japanese Society of Nephrology (JSN) has finalized guidelines designed to spur the development of new drugs for kidney disease. The guidelines aim to reduce the time, number of patients, and cost required for clinical trials through the use of…
To read the full story
Related Article
- Nephrology Society Poised to Compile Drug Development Guidelines for Early-Stage Kidney Disease
October 18, 2019
- Japanese Society of Nephrology Wins AMED Funding for “Surrogate Endpoint” Guidelines
August 8, 2016
- Japanese Society of Nephrology Aims to Promote Development through “Surrogate Endpoints”; Hopes to Draft Guidelines in FY2017
July 22, 2016
ACADEMIA
- Japan Atherosclerosis Society Proposes 3-Tier Lp(a) Risk Framework
September 16, 2026
- Clinical Value of Lp(a) Unchanged despite Pelacarsen PIII Miss: KOL
September 16, 2026
- Yanagisawa Wins Lasker Award for Unlocking Orexin’s Role in Sleep
September 10, 2026
- Generic Shortage Response Evolves into Wakayama’s 1st Regional Formulary
September 3, 2026
- Japan Cancer Database Initiative Aims to Bolster Trial Environment
August 26, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…